Trial Profile
A retrospective study comparing short and prolonged washout periods in multiple sclerosis patients switching from natalizumab to fingolimod therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Aug 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 20 Aug 2015 New trial record
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.